NurOwn ALS Stem Cell Trial Gets an FDA-Agreed Roadmap: What Phase 3b Means
When amyotrophic lateral sclerosis touches your family, every new announcement brings a wave of intense hope mixed with caution. You watch every press release, wondering if this is the moment research finally translates into a durable therapy. Families dealing with neurodegenerative conditions know how heavy this waiting game feels. We understand the profound desire for […]
Revolutionizing ALS Treatment: BrainStorm’s Phase 3b Trial Moves Forward with FDA Approval
BrainStorm Cell Therapeutics Inc., a leader in adult stem cell therapeutics for neurodegenerative diseases, has achieved a significant milestone with the FDA’s agreement on a Special Protocol Assessment (SPA) for its Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS). This agreement marks a critical step in advancing the potential treatment to the market, […]